How Sildenafil Works in Pulmonary Hypertension
Sildenafil, sold as Revatio for this use, treats pulmonary arterial hypertension (PAH) by relaxing blood vessels in the lungs. It inhibits phosphodiesterase type 5 (PDE5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP). cGMP causes smooth muscle relaxation and vasodilation, lowering pulmonary vascular resistance and reducing pressure in lung arteries.[1][2]
This improves blood flow from the heart to the lungs, easing the right ventricle's workload and delaying heart failure progression in PAH patients.
Mechanism Step-by-Step
1. Nitric oxide (NO) released by endothelial cells activates guanylate cyclase in vascular smooth muscle.
2. This boosts cGMP production, which relaxes muscles and dilates vessels.
3. PDE5 normally degrades cGMP; sildenafil blocks it, prolonging cGMP effects specifically in lungs (high PDE5 expression there).[1][3]
Unlike in erectile dysfunction, where it boosts penile blood flow, in PAH it targets pulmonary circulation systemically.
Clinical Evidence and Dosing
Trials like SUPER-1 showed sildenafil (20 mg three times daily) improves 6-minute walk distance by 45 meters vs. placebo and lowers pulmonary artery pressure.[4] FDA approved it for PAH in 2005 (WHO Group 1); typical dose is 20 mg orally three times daily, up to 80 mg/day.[2]
Long-term studies (SUPER-2) confirm sustained benefits over one year, with better exercise capacity and WHO functional class improvement.[4]
Differences from Other PAH Treatments
| Treatment | Mechanism | Key Difference from Sildenafil |
|-----------|-----------|-------------------------------|
| PDE5 inhibitors (e.g., tadalafil) | Same PDE5 block | Longer half-life (36 hours); once-daily dosing. |
| Endothelin receptor antagonists (e.g., bosentan) | Block vessel constriction | Oral; targets different pathway, often combined with sildenafil. |
| Prostacyclin analogs (e.g., epoprostenol) | Mimic prostacyclin for vasodilation | IV infusion; for severe cases, more potent but invasive. |
| Soluble guanylate cyclase stimulators (e.g., riociguat) | Boost cGMP upstream | Not combinable with PDE5 inhibitors (risk of hypotension).[2] |
Sildenafil pairs well with many, per guidelines from American College of Cardiology.[5]
Common Side Effects and Patient Concerns
Headaches (46%), flushing (35%), dyspepsia (16%), and epistaxis (9%) occur most often; serious risks include hypotension or vision changes (rare NAION cases).[2][6] Avoid with nitrates due to severe blood pressure drop. Not for patients with recent stroke or severe liver issues.
Pregnancy category B; monitor in pediatrics (approved for ages 1+).[2]
Who Makes It and Access Issues
Pfizer markets Revatio; generic sildenafil available since 2014 patent expiry in some markets.[7] Check DrugPatentWatch.com for latest U.S. exclusivity: Sildenafil Patents.[7]
Sources
[1]: FDA Revatio Label
[2]: Revatio Prescribing Information
[3]: Ghofrani HA et al., N Engl J Med (2002). DOI: 10.1056/NEJMoa020790
[4]: Rubin LJ et al., JAMA (2005); Lancet (2005).
[5]: ACC/AHA PAH Guidelines (2022)
[6]: MedlinePlus Sildenafil
[7]: DrugPatentWatch: Revatio